Evidence map›Paper›PMID 41324326›Full record

ArticleInvestigative ophthalmology & visual science2025

Corneal Myofibroblasts Suppress T-Cell Immunity in Corneal Transplantation.

Shudan Wang, Antonio Esquivel Herrera, Elsayed Elbasiony, Seokjoo Lee, Sharad K Mittal, Shima Dehghani, Akitomo Narimatsu, Hamid Alemi, Sunil K Chauhan, Reza Dana and 1 more

Abstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shudan WangCornea Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Antonio Esquivel HerreraCornea Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Elsayed ElbasionyCornea Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Seokjoo LeeCornea Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Sharad K MittalCornea Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Shima DehghaniCornea Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Akitomo NarimatsuCornea Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Hamid AlemiCornea Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Sunil K ChauhanCornea Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Reza DanaCornea Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Thomas H DohlmanCornea Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.

Funding

The Fibrosis-Immunity Interface in Corneal TransplantationK08EY031759 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI DOHLMAN, THOMAS · 2020 to 2024
$1.2M
The Fibrosis-Immunity Interface in Corneal TransplantationR01EY037257 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Thomas Dohlman · 2025 to 2026
$1.1M
NEI NIH HHS K08 EY031759NEI NIH HHS R01 EY037257
6 · The paper itself

Abstract

Purpose: To evaluate the immunoregulatory effect of corneal myofibroblasts on effector T cells derived from allogeneic corneal transplant recipient mice. Methods: Allo-primed CD4+CD25- effector T cells isolated from the draining lymph nodes of corneal transplant recipient mice were cocultured with corneal myofibroblasts or corneal fibroblasts. Flow cytometry was used to measure effector T-cell activation and function by expression of CD69, CD40L, and IFN-γ. Flow cytometry was also used to quantify T-cell apoptosis and T-cell proliferation upon coculture with corneal myofibroblasts. Results: Coculturing effector T cells with corneal myofibroblasts led to a significant decrease in effector T-cell activation as assessed by T-cell expression of CD69 (5520 ± 373 vs. 1701 ± 140) and CD40L (127.50 ± 4.17 vs. 42.87 ± 2.63) mean fluorescence intensity; this suppression was not seen with corneal fibroblasts. Coculture of T cells with myofibroblasts additionally led to a significant reduction in the frequency of IFN-γ+ effector T cells compared to coculture with fibroblasts (2.94% ± 0.85% vs. 0.65% ± 0.23%). Finally, compared to fibroblasts, coculture with myofibroblasts led to a significant increase in the frequency of apoptotic effector T cells (14.78% ± 3.67% vs. 32.48% ± 5.43%) and a significant reduction in T-cell proliferation (61.60% ± 2.68% vs. 39.63% ± 0.92%). Conclusions: Myofibroblasts are capable of suppressing T-cell immunity through suppression of effector T-cell proliferation, activation, and function, as well as the promotion of T-cell apoptosis. Our data suggest that in addition to their well-established role in extracellular matrix production, myofibroblasts may also actively participate in immunoregulation.

Indexed as

CorneaCorneal TransplantationMyofibroblastsT-LymphocytesAnimalsAntigens, CDApoptosisCD40 LigandCell ProliferationCells, CulturedCoculture TechniquesFibroblastsFlow CytometryInterferon-gammaLymphocyte ActivationMiceAntigens, CDCD40 LigandInterferon-gamma

Identifiers

PMID41324326
PMCPMC12697715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.